Although, the existing drugs used to treat many NTDs have serious limitations, only 1% of all new drugs to reach the market in the past 25 years were for neglected diseases .
Issues with current therapies include: cost; difficulties in administration; poor safety profile; and lack of efficacy e.g. In total, NTDs account for 5% of the global disease burden; yet, it is estimated only about 0.1% of global research budgets are spent on drug discovery for these diseases.
Malaria parasite chemotherapy; Emergence of resistance; New targets Malaria is a major human health problem causing high mortality and morbidity, mainly in Sub-Saharan Africa and in some parts of Asia and South America .
Malaria is caused by five Plasmodium species, namely, and high mortality is reported in infected children .
• Discuss pros/cons of peptidergic signalling system as source of anthelmintic targets.
• Identify proteins yielding deleterious phenotypes in helminth reverse genetic screens.
Malaria parasite has a complex life cycle  and transmitted to human by the bite of an infected female mosquito of the genus anopheles which harbours the parasite .
Received Date: October 31, 2015 Accepted Date: November 24, 2015 Published Date: November 30, 2015 Citation: Nigussie D, Beyene T, Shah NA, Belew S (2015) New Targets in Malaria Parasite Chemotherapy: A Review. doi:10.4172/2470-6965.1000S1-007 Copyright: © 2015 Nigussie D, et al.Address correspondence to this author at the Drug Discovery Unit, College of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK; Tel: (44)1382 385155; Fax: (44)1382 385542; E-mail: [email protected] This is an open access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US0 million for each drug to be successfully approved for clinical use.The rationale for identifying drug targets within helminth neuromuscular signalling systems is based on the premise that adequate nerve and muscle function is essential for many of the key behavioural determinants of helminth parasitism, including sensory perception/host location, invasion, locomotion/orientation, attachment, feeding and reproduction.This premise is validated by the tendency of current anthelmintics to act on classical neurotransmitter-gated ion channels present on helminth nerve and/or muscle, yielding therapeutic endpoints associated with paralysis and/or death.
Modern advancement in the biology of the parasite and different genomic techniques provide wide ranges of novel targets in the development of new therapy.